Clinical Trials

    Showing 1 - 3 of 3 Prostate Cancers

    Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)

    Status: Open Not Enrolling

    Investigator: Eleni Efstathiou

    Study Coordinator: Derek Cole

    Phone: 713.441.5607

    This is a phase 2 open label single arm study using an external control arm, to assess if the addition of darolutamide to ADT provides superior efficacy in terms of progression-free survival (PFS), as compared to ADT alone for men diagnosed with meta... Read more >

    Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Status: Open Not Enrolling

    Investigator: Eleni Efstathiou

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.... Read more >

    Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

    Status: Enrolling

    Investigator: Eleni Efstathiou

    Study Coordinator: Gabrielle Hayes

    Phone: 734.415.918

    This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.... Read more >